Literature DB >> 28615410

Causes and outcomes of markedly elevated C-reactive protein levels.

Alexander Landry1, Peter Docherty2, Sylvie Ouellette3, Louis Jacques Cartier4.   

Abstract

OBJECTIVE: To characterize the causes of marked elevation of C-reactive protein (CRP) levels, investigate patient outcomes, and examine factors that might influence the CRP response.
DESIGN: Health records were used to retrospectively determine patient characteristics, diagnoses, and outcomes over a 2-year period (2012 to 2013).
SETTING: A large referral centre in Moncton, NB. PARTICIPANTS: Adult inpatients and outpatients with a CRP level above 100 mg/L. MAIN OUTCOME MEASURES: Differences among the CRP distributions of various diagnosis categories were examined using Kruskal-Wallis tests, and factors affecting outcomes were examined using Fisher exact tests.
RESULTS: Over the 2-year period, 1260 CRP levels (839 patients; 3.1% of all tests) were above 100 mg/L (range 100.1 to 576.0 mg/L). The mean age was 63 years (range 18 to 101) and 50.2% of patients were men. Infection was the most prevalent cause (55.1%), followed by rheumatologic diseases (7.5%), multiple causes (5.6%), other inflammatory conditions (5.4%), malignancy (5.1%), drug reactions (1.7%), and other conditions (2.0%). A diagnosis could not be established in 17.6% of cases. On average, infections caused higher peak CRP levels (W = 34 519, P < .001) and infection was present in 88.9% of cases with CRP levels greater than 350 mg/L. Rheumatologic causes were associated with only 5.6% of CRP levels above 250 mg/L. The overall mortality was 8.6% and was higher in patients with malignancy (37.0%), multiple diagnoses (21.0%), and leukopenia (20.7%, P = .002).
CONCLUSION: Most patients had infections and the proportion of patients with infections increased with the level of CRP, although many diagnoses were associated with markedly elevated CRP levels. These data could help guide health care professionals in the evaluation and management of these patients. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28615410      PMCID: PMC5471098     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  7 in total

Review 1.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 2.  C-reactive protein and systemic lupus erythematosus.

Authors:  Shilpa Gaitonde; David Samols; Irving Kushner
Journal:  Arthritis Rheum       Date:  2008-12-15

Review 3.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

4.  Serum C-reactive protein levels in disease.

Authors:  J J Morley; I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  C-reactive protein and risk of lung cancer.

Authors:  Anil K Chaturvedi; Neil E Caporaso; Hormuzd A Katki; Hui-Lee Wong; Nilanjan Chatterjee; Sharon R Pine; Stephen J Chanock; James J Goedert; Eric A Engels
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

6.  Extremely elevated C-reactive protein.

Authors:  Steven Vanderschueren; Dries Deeren; Daniël C Knockaert; Herman Bobbaers; Xavier Bossuyt; Willy Peetermans
Journal:  Eur J Intern Med       Date:  2006-10       Impact factor: 4.487

7.  C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.

Authors:  Wolfgang Koenig; Hannelore Löwel; Jens Baumert; Christa Meisinger
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

  7 in total
  26 in total

1.  Evaluation of incidental pelvic fluid in relation to physiological changes in healthy pubescent children using pelvic magnetic resonance imaging.

Authors:  Ashkan Tadayoni; Faraz Farhadi; S Mojdeh Mirmomen; Ahmad Shafiei; Karen F Berman; Mohammadhadi Bagheri; Pedro E Martinez; Peter J Schmidt; Jack A Yanovski; Ashkan A Malayeri
Journal:  Pediatr Radiol       Date:  2019-03-12

2.  C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.

Authors:  Daniel C McFarland; Kelly Shaffer; William Breitbart; Barry Rosenfeld; Andrew H Miller
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

3.  Longitudinal changes of inflammatory biomarkers moderate the relationship between recent stressful life events and prospective symptoms of depression in a diverse sample of urban adolescents.

Authors:  Marin M Kautz; Christopher L Coe; Brae Anne McArthur; Naoise Mac Giollabhui; Lauren M Ellman; Lyn Y Abramson; Lauren B Alloy
Journal:  Brain Behav Immun       Date:  2019-02-26       Impact factor: 7.217

4.  Factors Associated With Elevated Inflammatory Markers Prior to Shoulder Arthroplasty.

Authors:  Kyle J Kopechek; Gregory L Cvetanovich; Joshua S Everhart; Travis L Frantz; Richard Samade; Julie Y Bishop; Andrew S Neviaser
Journal:  HSS J       Date:  2021-03-20

5.  Comparing different operationalizations of allostatic load measured in mid-life and their patterning by race and cumulative life course socioeconomic status.

Authors:  Katrina L Kezios; Shakira F Suglia; David Matthew Doyle; Ezra Susser; Gary Bradwin; Piera Cirillo; Barbara Cohn; Bruce Link; Pam Factor-Litvak
Journal:  Psychoneuroendocrinology       Date:  2022-02-12       Impact factor: 4.905

6.  Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy.

Authors:  Lelia H Chaisson; Fred C Semitala; Lucy Asege; Sandra Mwebe; Jane Katende; Martha Nakaye; Alfred O Andama; Carina Marquez; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

7.  Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure.

Authors:  Kusum S Mathews; Howard Soh; Shahzad Shaefi; Wei Wang; Sonali Bose; Steven Coca; Shruti Gupta; Salim S Hayek; Anand Srivastava; Samantha K Brenner; Jared Radbel; Adam Green; Anne Sutherland; Amanda Leonberg-Yoo; Alexandre Shehata; Edward J Schenck; Samuel A P Short; Miguel A Hernán; Lili Chan; David E Leaf
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 7.598

8.  Extremely high canine C-reactive protein concentrations > 100 mg/l - prevalence, etiology and prognostic significance.

Authors:  Sarah Hindenberg; Natali Bauer; Andreas Moritz
Journal:  BMC Vet Res       Date:  2020-05-20       Impact factor: 2.741

9.  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.

Authors:  Shruti Gupta; Wei Wang; Salim S Hayek; Lili Chan; Kusum S Mathews; Michal L Melamed; Samantha K Brenner; Amanda Leonberg-Yoo; Edward J Schenck; Jared Radbel; Jochen Reiser; Anip Bansal; Anand Srivastava; Yan Zhou; Diana Finkel; Adam Green; Mary Mallappallil; Anthony J Faugno; Jingjing Zhang; Juan Carlos Q Velez; Shahzad Shaefi; Chirag R Parikh; David M Charytan; Ambarish M Athavale; Allon N Friedman; Roberta E Redfern; Samuel A P Short; Simon Correa; Kapil K Pokharel; Andrew J Admon; John P Donnelly; Hayley B Gershengorn; David J Douin; Matthew W Semler; Miguel A Hernán; David E Leaf
Journal:  JAMA Intern Med       Date:  2021-01-01       Impact factor: 21.873

10.  Increased C-reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and meta-analysis.

Authors:  Alessandro Miola; Veronica Dal Porto; Tal Tadmor; Giovanni Croatto; Paolo Scocco; Mirko Manchia; Andre F Carvalho; Michael Maes; Eduard Vieta; Fabio Sambataro; Marco Solmi
Journal:  Acta Psychiatr Scand       Date:  2021-08-25       Impact factor: 7.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.